Abstract
Inherited cardiac channelopathies are linked to a heightened risk of sudden cardiac death. Despite evolving knowledge on different genes for these inherited conditions, for certain subtypes, such as catecholaminergic polymorphic ventricular tachycardia syndrome, the specific genetic causes remain unidentified. The research of the pathophysiological mechanisms underlying catecholaminergic polymorphic ventricular tachycardia syndrome has been conducted through different in vitro and in vivo models, including genetically modified animal models, cardiac‐specific transgenic models, pharmacological interventions in animal models, human‐induced pluripotent stem cell–derived cardiomyocytes in 2‐ and 3‐dimensional cardiac models. Recent research predominantly utilizes human‐induced pluripotent stem cell–derived cardiomyocytes, focusing on genotype–phenotype correlations and pharmacological screening. The integration of cutting‐edge techniques such as clustered regularly interspaced short palindromic repeats/Cas9 genome editing and 3‐dimensional–engineered heart tissues has shed new light on the pathophysiological mechanisms of catecholaminergic polymorphic ventricular tachycardia, potentially enhancing drug therapies as part of personalized medicine approaches. This review emphasizes the diverse insights gained from both in vivo and in vitro studies of catecholaminergic polymorphic ventricular tachycardia, along with the application of these models in various research contexts.
Keywords: 3‐dimensional engineered heart, catecholaminergic polymorphic ventricular tachycardia, CRISPR/Cas9 genome editing, electrophysiological phenotyping, human‐induced pluripotent stem cell‐derived cardiomyocytes, precision medicine in cardiac channelopathies, preclinical cardiovascular models
Subject Categories: Arrhythmias, Stem Cells, Pathophysiology, Animal Models of Human Disease, Gene Therapy
Nonstandard Abbreviations and Acronyms
- CASQ2
cardiac calsequestrin 2
- CPVT
catecholaminergic polymorphic ventricular tachycardia
- CRISPR
clustered regularly interspaced short palindromic repeats
- DAD
delayed afterdepolarization
- EHT
engineered heart tissue
- hiPSC‐CM
human‐induced pluripotent stem cell–derived cardiomyocyte
- iPSC‐CM
induced pluripotent stem cell–derived cardiomyocyte
- RyR2
ryanodine receptor 2
- SAN
sinoatrial node
- SR
sarcoplasmic reticulum
- TECRL
trans‐2,3‐enoyl‐CoA reductase‐like protein
Catecholaminergic Polymorphic Ventricular Tachycardia in Clinical Perspective
Epidemiology and Genetic Recognition of Catecholaminergic Polymorphic Ventricular Tachycardia
Catecholaminergic polymorphic ventricular tachycardia (CPVT) was first recognized as a unique inherited arrhythmogenic syndrome in 1975. 1 In 1999, an autosomal dominant pattern of inheritance was described, with its first genetic locus located on chromosome 1q42‐43. 2 Most CPVT cases are associated with variants in the RYR2 (ryanodine receptor 2) gene. 3 Triggered by emotional stress or physical exertion, CPVT manifests in individuals without structural heart disease, leading to adrenergic‐induced bidirectional or polymorphic ventricular tachycardia (Figure 1A). 4 Its prevalence in Europe is estimated at 1 in 10 000 and can result in sudden cardiac death. Children and adolescents are commonly affected, with a notably poor prognosis for those experiencing early syncope. 5 Untreated, CPVT has a high mortality rate, with up to 31% of patients dying by the age of 30. 6
Figure 1. Main characteristics and critical mechanism of CPVT.

A, Typical ECG of a patient with CPVT, characterized by abrupt sequences of polymorphic ventricular complexes that punctuate the baseline rhythm. B, Comprehensive listing of all reported genes related to CPVT. C, Calcium dynamics in a CPVT cardiomyocyte: Normal Ca2+ influx via L‐type Ca2+ channels during depolarization (systole) triggers RYR2 to release Ca2+ from the sarcoplasmic reticulum. In contrast, RYR2 mutations induce an abnormal Ca2+ leak during repolarization (diastole), resulting in Ca2+ overload. The NCX1 attempts to expel excess Ca2+ from the cytosol by exchanging it for Na+. This generates an inward Na+ current, contributing to delayed afterdepolarizations. D, *Early after depolarization and **delayed after polarization. Figure 1C created using Smart Servier Medical Art. CPVT indicates catecholaminergic polymorphic ventricular tachycardia; NCX1, Na+/Ca2+ exchanger; and RYR2, cardiac ryanodine receptor.
Current Treatment Approaches
Treatment of CPVT involves a comprehensive approach that emphasizes symptoms without clear evidence from large‐scale trials. β Blockers, particularly those without sympathomimetic effects, are first‐line treatments to reduce syncope and control arrhythmias. 7 However, managing CPVT can be complex, especially when patients exhibit ventricular tachycardia during exercise. 8 For those inadequately responsive to β blockers, calcium channel blockers like diltiazem or verapamil have been found to stabilize heart rhythms. 9 Additionally, flecainide, combined with β blockers, can decrease the risk of ventricular tachyarrhythmias. 10 It is essential to highlight that the efficacy of these drugs can vary among patients with CPVT with different gene variants, and it is not yet fully understood if these treatments are universally effective across all CPVT types. Patients with acute cases of CPVT and left cardiac sympathetic denervation surgery may be needed to regulate sympathetic nerve activity and reduce arrhythmias. 5 Concurrently, patients at increased risk for sudden cardiac death may require the implantation of an implantable cardioverter‐defibrillator to prevent fatal arrhythmic events. 11 Lifestyle adaptations are crucial in CPVT management. Avoidance of strenuous physical activities and intense emotional stress, known triggers of arrhythmic episodes, is advised. 5 The European Heart Rhythm Association discourages participation in competitive and high‐intensity sports for patients with CPVT, recommending low‐ to moderate‐intensity activities under certain conditions, like passing a stress test and remaining symptom free for a minimum of 3 months. The European Heart Rhythm Association advises asymptomatic CPVT variant carriers to engage in low‐intensity sports and suggests that patients with CPVT adopt an exercise routine similar to the general population's standards. 12 In line with the 2022 European Society of Cardiology guidelines, there is now an increased emphasis on genetic testing and cardiac magnetic resonance imaging for risk stratification in patients with CPVT, and the guidelines advocate for personalized management plans. 13
CPVT's Molecular Puzzle and Pathophysiology
The variants in genes for RYR2 and CASQ2 (cardiac calsequestrin 2) define CPVT. 14 RYR2, a tetrameric protein on the sarcoplasmic reticulum (SR) membrane, facilitates ion release during systole (Figure 1). 15 It is tethered to CASQ2 through satellite proteins. 16 Associated with RYR2's cytoplasmic region are calmodulin, FKBP12.6 (calstabin2), protein kinase A, phosphatase 1, and phosphatase 2, while triadin links to the luminal side. 17 Crucial to CPVT pathophysiology is calcium homeostasis. Variants in RYR2 and CASQ2 disrupt cardiac cellular calcium signaling. These alterations in calcium regulation lead to atypical Ca2+ release under sympathetic stimulation. 18
The genetic heterogeneity of CPVT can be further understood by distinguishing between its 2 main subtypes: CPVT1 and CPVT2. CPVT1 is primarily associated with mutations in the gene encoding the RYR2. Mutations in this gene lead to abnormal calcium release from the SR. CPVT2, on the other hand, is linked to mutations in the gene encoding CASQ2. This gene is crucial for calcium storage within the SR. Mutations in CASQ2 disrupt calcium homeostasis, similarly, leading to arrhythmogenic events. 19 Both CPVT1 and CPVT2 variants typically cause SR calcium leakage, triggering delayed afterdepolarizations (DADs) via cytosolic calcium accumulation (Figure 1B). The released Ca2+ activates the Na+/Ca2+ exchanger, producing transient inward currents and potential DADs, heightening arrhythmia risk. Conversely, early afterdepolarizations emerge during action potential plateaus or repolarization, overlapping with CPVT symptoms. Apart from RYR2 gene variants, CPVT also involves less common genetic changes in triadin, calmodulin genes (CALM1, CALM2, CALM3), ankyrin‐B (ANK2), and Trans‐2,3‐enoyl‐CoA reductase‐like protein (TECRL), a gene involved in calcium homeostasis and linked to an autosomal recessive form of CPVT (Figure 1B). 20 However, the role of KCNJ2, PKP2, and SCN5A genes in CPVT is now primarily discounted, with the prevalent ANK2 gene variant unlikely to be a primary CPVT factor. 20 In 2016, the TECRL mutation's link to CPVT was first reported. 21 Recent studies on TECRL knockout mice also indicate mitochondrial function alterations. 22 Pathomechanisms for CPVT include theories like weakened RYR2 and FKBP12.6 binding, causing FKBP12.6 dissociation and channel leakage during diastole. 23 The store‐overload–induced Ca2+ release hypothesis suggests a lowered store‐overload–induced calcium release threshold in RYR2 mutants, causing SR Ca2+ overflow. 24 Another perspective involves defective intramolecular domain interaction, leading to SR Ca2+ leakage. 25 Additionally, patients with CPVT may experience ventricular fibrillation. This can arise from irregular automaticity of Purkinje fibers. Such irregularities lead to abnormalities in cardiac impulse propagation. 26 Elevated catecholamine levels, a key trigger for ventricular arrhythmias in CPVT, amplify the response to sympathetic stimulation. 27 Variants affecting the ß‐adrenergic signaling pathway and overactivity of the calmodulin‐dependent kinase II pathway in individuals with ryanodine receptor variants are also implicated in CPVT. 28
Experimental Models of CPVT
The study of CPVT has been dramatically advanced using both in vivo and in vitro models, each offering unique insights into the disease's mechanisms and potential treatments (Figure 2). In vivo models are crucial for understanding CPVT's systemic physiological and pathophysiological responses. These models allow researchers to observe the disease's progression and response to therapies in a complex living system, closely mirroring the human condition (Table 1). 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36
Figure 2. Overview of in vivo and in vitro models in CPVT research.

This figure illustrates the main models used to investigate CPVT pathophysiological mechanisms. In vivo models include animal models such as rodents and rabbits, genetically modified animals that mimic the human disease phenotype, enabling the study of disease progression and therapeutic interventions, and drug‐induced models to probe the electrophysiological properties and response to therapeutic interventions. In vitro models encompass cellular constructs, iPSC‐CMs, and tissue engineering approaches. Both in vivo and in vitro models benefit from genetic and molecular studies such as CRISPR/Cas9 gene editing, which help elucidate gene function and validate therapeutic targets. The schematic also represents the translation from clinical ECG diagnosis to research model application, highlighting the bidirectional flow of insights between patient‐derived data and experimental findings. Image created using Smart Servier Medical Art. CPVT indicates catecholaminergic polymorphic ventricular tachycardia; CRISPR, clustered regularly interspaced short palindromic repeats; and iPSC‐CMs, induced pluripotent stem cell–derived cardiomyocytes.
Table 1.
Experimental Models for CPVT
| Model | Methods | Advantages | Disadvantages | |
|---|---|---|---|---|
| Animal models | Transgenic mouse model (RYR2 variant) 29 | Creating transgenic models where specific genes are introduced or overexpressed | Direct observation of pathophysiological effects; suitable for long‐term studies | Limited by differences in cardiac physiology compared with humans |
| Genetically modified animal model 30 | It encompasses various genetic modifications including knock‐ins, knockouts, and transgenics | Allows exploration of gene function and interaction in vivo; more versatile than specific transgenic models | Ethical considerations; may not fully replicate human disease mechanisms | |
| Rat models 31 | Transgenic expression, pharmacological induction | Allows study of specific protein interactions; useful for drug testing | May not fully replicate human arrhythmic triggers | |
| Rabbit model (sex differences) 32 | Electrophysiological studies on ion currents and calcium handling | Insight into sex‐specific electrophysiological differences; applicable to understanding human sex differences | Complex handling and transgenic model are difficult to obtain | |
| Zebrafish model 33 | CRISPR/Cas9 for targeted gene mutations | Rapid development, ease of genetic manipulation; translucency allows direct observation of cardiac function | Cardiac anatomy and function may not fully replicate human conditions | |
| hiPSC‐CMs | hiPSCs‐CM models 34 | CRISPR/Cas9 for gene editing, calcium imaging, patch‐clamping | Patient‐specific modeling; high relevance to human cellular responses | Lack of cardiac markers; complexity in differentiation and maturation; high variability |
| 3‐dimensional cardiac tissue model 35 | Tissue engineering with iPSC‐CMs, mechanical and electrical stimulation | Mimics in vivo microenvironment; integrates cellular interactions and mechanics | Technically challenging; expensive to develop and maintain | |
| Computational models | Computational simulation 36 | Simulation of ion channel dynamics and cardiac electrophysiology | Hypothesis testing without ethical constraints; integrates vast data sets to predict outcomes | Depends on model accuracy; may not mirror all biological complexities |
CPVT indicates catecholaminergic polymorphic ventricular tachycardia; CRISPR, clustered regularly interspaced short palindromic repeats; hiPSC‐CM, human‐induced pluripotent stem cell–derived cardiomyocyte; and iPSC‐CM, induced pluripotent stem cell–derived cardiomyocyte.
Animal Models in CPVT Research
Mohamed et al discuss using transgenic knock‐in mouse models to elucidate the pathophysiological mechanisms underlying CPVT. These models harbor specific mutations in the RYR2 or CASQ2 genes, which correlate with the autosomal dominant and recessive forms of CPVT, respectively. The research demonstrated that CPVT‐associated arrhythmias originate from DADs and triggered activities, providing insight into the molecular and electrophysiological basis of the disease. 37 , 38 Recent advances also highlight the use of zebrafish as an in vivo model for inheritable ventricular arrhythmia syndromes. Zebrafish share remarkable similarities with humans in cardiac electrophysiology, and advanced gene editing and electrophysiological phenotyping methods are available. 33
Molecular Mechanisms and Calcium Handling in Animal Models
Diving deeper into molecular mechanisms, Veress et al provided insights into the role of endoplasmic reticulum stress in contributing to cardiac arrhythmias CPVT. 38 Using a rat model of CPVT induced by the RyR2‐S2222L (+/−) variant, they observed that CPVT ventricular myocytes under β‐adrenergic stimulation exhibit a heightened propensity to spontaneous Ca2+ waves and DADs. Further exploring molecular interactions, Veress et al also explored the diverse arrhythmia phenotypes caused by mutations in CALM2 and CALM3. Their research revealed that, while mutations in CALM2 lead to a mixed phenotype resembling that in CPVT, mutations in CALM3 result in typical CPVT characteristics. They demonstrated that both CALM2 D132E and CALM3 D132E rats exhibit defective intracellular Ca2+ handling, impacting the function of both RYR2 and L‐type calcium channels. Shifting the focus to cellular metabolism, a recent study has shed light on the role of mitochondria in mitigating the harmful effects of aberrant Ca2+ release in CPVT. Mitochondrial phosphate transport, known to influence mitochondrial calcium uptake and buffering, is hypothesized to impact arrhythmogenesis in CPVT. In experiments using a CPVT mouse model (CASQ2 knockout), modulation of mitochondrial phosphate transport through pharmacological inhibition or manipulation of cytosolic phosphate concentration significantly affected cellular calcium dynamics and arrhythmic burden. 39 Examining sex‐specific aspects, Horváth et al investigated sex differences in Na+ and Ca2+ handling properties in rabbit atrial cardiomyocytes. 32 In their study using adult male and female rabbits and female rabbits treated with dihydrotestosterone, they assessed ion currents and calcium‐handling properties to investigate potential sex differences in atrial electrophysiology. Additionally, the study observed that females generally exhibited larger forward Na+/Ca2+ exchanger currents than males. Moreover, calcium transient measurements showed that females had higher diastolic Ca2+ and Ca2+ transient amplitude. This study provides valuable insights into sex‐specific differences in cardiac electrophysiology in CPVT, which could inform our understanding of conditions like CPVT and guide sex‐specific therapeutic strategies. Further contributing to our molecular understanding, the study by Lin et al studied the effects of TECRL deficiency on cardiometabolic and Ca2+ regulation in cardiac tissue, shedding light on potential mechanisms underlying CPVT. 40 They establish TECRL knockout mice and conduct RNA‐sequencing analysis, identifying 857 differentially expressed genes in TECRL knockout mice. Advancing the discussion to β‐adrenergic receptor signaling, Pavlaki et al used mouse models to selectively disrupt integral components of β‐adrenergic receptor signaling and gain mechanistic insight into CPVT pathogenesis. 41 They found that abnormal Ca2+ release events induced by hyperactivated L‐type calcium channels contributed to arrhythmia incidence, suggesting a link between β‐adrenergic receptor stimulation, L‐type calcium channel–mediated calcium increase, and CPVT development. The observed change in L‐type calcium channel activity constitutes pathogenic hyperactivation, not merely an increase in current flow. Investigating sinoatrial node (SAN) dysfunction, Neco et al investigated the SAN dysfunction in mice carrying the CPVT‐linked RyR2R4496C variant. 42 Their findings revealed that these mice exhibited impaired SAN automaticity following β‐adrenergic stimulation, mirroring the SAN dysfunction seen in CPVT patients after exercise. The study observed slower pacemaker activity, reduced chronotropic response in RYR2R4496C SAN cells, and increased frequency of Ca2+ sparks. Interestingly, they found that this variant led to a paradoxical decrease in SAN automaticity due to a Ca2+‐dependent reduction of the L‐type Ca2+ current and sarcoplasmic reticulum Ca2+ depletion during diastole. Following up on the SAN dysfunction observed in the study by Neco et al., the long‐term findings from Veith et al provide crucial clinical context. Despite β blocker use and additional flecainide when needed, patients with CPVT still faced a high rate of ventricular tachycardia and fibrillation. 43 In an interesting contribution, the study by Yin et al investigated the arrhythmogenic mechanisms of a mutation in the RYR2 N‐terminal domain associated with CPVT. 44 They observed ventricular tachycardias in both patients with CPVT and knock‐in mice harboring the variant, along with increased DADs and Ca2+ waves in cardiomyocytes carrying the variant.
Therapeutic Insights and Gene Therapy in Animal Models
Transitioning to therapeutic insights, Blackwell et al provided insights into the anatomic origin of CPVT. They focused on genetic manipulation in mice, elucidating that these arrhythmias likely emanate from the Purkinje myocardial junction. 45 Integrating this discovery into the broader landscape of CPVT research enhances our understanding of the condition's pathogenesis and may open new avenues for targeted therapeutic interventions. Turning to gene therapy, a recent study by Moore et al, the long‐term efficacy and safety of cardiac genome editing for CPVT were investigated. 46 Using an innovative approach with adeno‐associated virus type 9–mediated somatic genome editing, the researchers targeted the mutant RYR2 allele in mice heterozygous for the R176Q variant. Remarkably, this intervention led to a 100% reduction in ventricular tachyarrhythmias compared with controls at 6 weeks after injection, a reduction maintained even after 12 months. In a similar vein, Denegri et al demonstrated that a single delivery of adeno‐associated virus type 9–CASQ2 in newborn R33Q mice prevented the development of CPVT and effectively reduced the CPVT phenotype in adult mice. 47 Innovatively using gene therapy, Santiago Castillo et al studied the potential of cardiac CASQ2 overexpression as a gene therapy treatment for CPVT1. Their results showed a significant reduction in arrhythmias in treated mice compared with untreated ones, proving that CASQ2 overexpression could be an effective and safe therapeutic strategy for CPVT1. 48 Exploring pharmacological interventions, the study by Ritschel et al investigated the efficacy of the RYR2‐selective inhibitor ent‐(+)‐verticilide in preventing ventricular arrhythmias with chronic and oral dosing. 49
Pharmacological Investigations in Animal Models
Identifying new therapeutic avenues, Reyes Gaido et al identified ruxolitinib as a potent inhibitor of calmodulin‐dependent kinase II activity, offering a potential treatment avenue for cardiac arrhythmias. 50 , 51 Through a drug repurposing screen using an improved fluorescent reporter, they effectively found ruxolitinib to inhibit calmodulin‐dependent kinase II in cultured cardiomyocytes and mouse models. Assessing drug effectiveness, Hwang et al evaluated the effectiveness of class I antiarrhythmic drugs on RYR2 channels. 52 In a CPVT cellular model (CASQ2−/− myocytes), both flecainide and propafenone significantly reduced arrhythmogenic calcium waves. In CASQ2−/− mice, both propafenone enantiomers effectively prevented exercise‐induced bidirectional tachycardia in CPVT cardiomyocytes. The study by Watanabe et al highlighted a specific therapeutic agent and demonstrated the effectiveness of other class 1 antiarrhythmic drugs like flecainide in treating CPVT in both mice and humans. 53 It revealed that flecainide inhibits RYR2 receptor‐mediated calcium release. This drug successfully prevented arrhythmias in a CPVT mouse model and completely halted CPVT symptoms in 2 patients who had not responded to conventional treatments. Investigating flecainide's mechanism of action, in the study by Kryshtal et al, the effectiveness of flecainide in treating CPVT was explored. 54 Using N‐methylated flecainide analogs, which blocked sodium channels but not RYR2 channels, they demonstrated that these analogs did not prevent arrhythmias in a CPVT mouse model. The study by Bueno‐Levy et al examined ivabradine's effectiveness in treating CPVT by examining ivabradine's efficacy. 55 The study tested ivabradine on human‐induced pluripotent stem cell‐derived cardiomyocytes (hiPSC‐CMs) from patients with CPVT, SAN calcium transients, and on ECG measurements from a transgenic mouse model of CPVT. Developing patient‐specific models, in the study by Di Pasquale et al., a patient‐specific model for CPVT was developed using human‐induced pluripotent stem cell‐derived cardiomyocytes (hiPSC‐CMs). 56 The study demonstrated that treatment with the calmodulin‐dependent kinase II inhibitor KN‐93 significantly reduced DADs. Additionally, the antiarrhythmic effect of KN‐93 was confirmed in these hiPSC‐CMs, which paralleled findings in RYR2 knock‐in CPVT mice. For pharmacokinetic analysis, Blackwell et al conducted an in‐depth analysis of ent‐verticilide's pharmacokinetic and pharmacodynamic properties in a murine model of CPVT. Ent‐verticilide is an enantiomer of verticilide, a selective and potent inhibitor of RYR2. In their study, Blackwell et al found that ent‐verticilide exhibits enhanced stability in plasma compared with its natural counterpart, nat‐verticilide, making it more suitable for pharmacological applications. 57 Adding to these advancements, Liu et al conducted an in vivo study on CPVT using a calsequestrin‐associated mouse model. Their research centered on engineering a calmodulin protein to normalize the RYR2 refractory period, which is crucial in CPVT development. 30 Despite the invaluable insights provided by animal models (Figure 2), their limitations in statistical power and relevance to human physiology should be emphasized. The differences in cardiac physiology between animals and humans can affect the translation of findings. 58 Also, many animal studies are conducted with relatively small sample sizes, which may compromise the statistical significance of the observed effects. This is particularly important for studies focused on gene therapy interventions, where the variability in genetic backgrounds between animal subjects can further complicate the interpretation. 59
hiPSC‐CM MODEL
Human‐Induced Pluripotent Stem Cell–Derived Cardiomyocytes
In vitro models are important for the study of CPVT. These models include mainly induced pluripotent stem cell–derived cardiomyocytes (iPSC‐CMs) in 2‐dimensional models and 3‐dimensional cardiac tissue models. iPSCs‐CMs are particularly significant as they are generated from patient‐specific iPSCs, carrying the same genetic variants, which allows for the exploration of disease mechanisms and drug responses in a personalized context (Figure 2). Genome‐edited iPSC lines, often modified using techniques like clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9, are used to induce specific genetic variants and to study the phenotype. In another manner an available variant can be corrected using CRISPR/Cas9 to reverse the phenotype. The recent development of 3‐dimensional cardiac tissue models offers a more physiologically relevant environment for studying cardiac channelopathies. The advantage of 3‐dimensional cardiac tissue models lies in their ability to better mimic the in vivo microenvironment of the heart, including cell–cell and cell–matrix interactions, mechanical properties, and chemical signaling, compared with traditional 2‐dimensional culture models. 60
hiPSC‐CM Model for Precision Medicine
These in vitro models are essential in elucidating the cellular and molecular underpinnings of CPVT and in screening potential pharmacological treatments, enhancing our understanding and management of CPVT. This method has yielded crucial cardiomyocyte models tailored to individual patients, uncovering detailed molecular anomalies and ion channel behavior essential to CPVT. This advancement has driven the creation of customized therapeutic solutions, advancing precision medicine in treating this genetic disorder. Many studies, as listed in Table 2, highlight the significance of hiPSCs in CPVT research, demonstrating their extensive potential as in vitro models. Li et al's research confirms that CPVT‐hiPSCs retain a normal karyotype, thus affirming their accuracy in simulating cardiomyocyte pathology linked to CPVT. Although maintaining a normal karyotype is a fundamental criterion, it ensures that the genetic integrity of the hiPSCs remains preserved, free from chromosomal abnormalities. 61 Jung et al produced CPVT patient‐specific iPSC‐CMs with the RYR2 S406L variant. These cells showed elevated diastolic Ca2+ levels, reduced SR Ca2+ content, and increased arrhythmic risk under stress, indicating faulty Ca2+ regulation. 62 Pölönen et al studied CPVT–hiPSC‐CMs with RYR2 E3D and L4115F mutations, finding unique action potential characteristics under adrenaline that led to pronounced arrhythmic tendencies. 63 Carvedilol and flecainide reduced arrhythmic impacts but also decreased cell contraction amplitude. Itzhaki et al developed CPVT‐hiPSCs from dermal fibroblasts of a patient with a unique M4109R RyR2 mutation. 64 These cells were differentiated into cardiomyocytes and compared with those from healthy controls, revealing significant internal Ca2+ handling abnormalities in CPVT cardiomyocytes, contributing to CPVT's pathological manifestations. Similarly, Preininger et al used hiPSC‐CMs to study CPVT, focusing on a patient with a unique RYR2 mutation who responded poorly to nadolol but well to flecainide. 65 The hiPSC‐CMs showed altered Ca2+ homeostasis. Nadolol failed to correct this, while flecainide was effective, matching the patient's response. Both studies highlight the value of hiPSC‐CMs in modeling CPVT, providing insights into arrhythmic processes and drug evaluations. CPVT arises from dysfunctional intracellular Ca2+ regulation due to mutations in either the RYR2 or CASQ2 genes. Novak et al and Nijak et al found that mutated CASQ2 and RYR2 hiPSC‐CMs were less developed and had atypical responses to isoproterenol, causing arrhythmias or increased diastolic [Ca2+]i, unlike controls. 66 , 67 This underscores hiPSC‐CMs' role in understanding the distinct effects of RYR2 and CASQ2 mutations in CPVT. Maizels et al used hiPSCs from a CPVT2 patient with a D307H‐CASQ2 mutation and observed irregularities in Ca2+ handling and an increased susceptibility to arrhythmias. 68 They tested several drugs, with carvedilol and JTV‐519 stabilizing the SR and preventing arrhythmias. In a study, Gao et al found that hiPSC‐CMs from a CPVT patient with the CALM2 p.E46K variant had severe electrical and calcium handling issues due to increased Ca2+ leakage through RYR2. 69 The E46K‐calmodulin variant strongly enhanced RYR2 function. Nadolol and flecainide effectively reduced these abnormalities, suggesting potential treatments. The ongoing research utilizing hiPSC‐CMs continues to demonstrate considerable promise for developing personalized treatments and further enhancing understanding in the CPVT field. hiPSC‐CMs effectively model the CPVT2 phenotype, offering valuable insights into the disease's mechanisms and potential patient‐specific treatments. 68 Overall, the ability of hiPSC‐CMs to accurately model patient‐specific cardiomyocyte pathology has been crucial in understanding CPVT and exploring potential therapeutic interventions. 68
Table 2.
Summarizes Preclinical Studies on CPVT Syndrome
| References | Organism/origin | Gene | Variant | Pharmacological/biological therapeutic interventions |
|---|---|---|---|---|
| Mohamed et al 37 | Mouse | RYR2 | ‐ | Testing β blockers to prevent arrhythmias |
| Veress et al 38 | Rat |
Calm2 Calm3 |
D132E | β‐Adrenergic blockade to manage ventricular tachycardia; potential interventions targeting both RYR2 and LTCC dysfunction caused by impaired calmodulin interactions |
| Deb et al 39 | Mouse | CASQ2 | Knockout | Modulation of mitochondrial phosphate transport to enhance Ca buffering via inhibitors, cytosolic phosphate adjustment, or phosphate transporter overexpression |
| Horváth et al 32 | Rabbit (male, female, dihydrotestosterone‐treated females) | ‐ | ‐ | Dihydrotestosterone treatment to enhance L‐type Ca2+ current density; investigation of forward Na+/Ca2+ exchanger and calcium handling to assess sex‐based differences in arrhythmogenesis |
| Lin et al 40 | Mouse | TECRL | Knockout | Targeting fatty acid metabolism and calcium‐handling pathways; potential inhibition of calmodulin‐dependent kinase II and modulation of metabolic processes |
| Pavlaki et al 41 | Mouse | ‐ | ‐ | Targeting β‐adrenergic receptor signaling via adeno‐associated virus type 9‐mediated delivery or CRISPR/CAS9‐AAV9‐based somatic mutagenesis (CASAAV) to disrupt LTCC regulation and calmodulin‐dependent kinase II hyperactivity |
| Neco et al 42 | Mouse | RYR2 | R4496C | β Blockers, sodium channel blockers (flecainide, propafenone) to manage CPVT; investigation of SAN dysfunction and Ca2+‐handling impairments |
| Yin et al 44 | hiPSC‐CMs and mouse (knock‐in) models | RYR2 | R420Q | β Blockers and stress management for CPVT |
| Blackwell et al 45 | Mouse | CASQ2 | ‐ | Endocardial ablation or restoring CASQ2 expression in subendocardial cardiomyocytes near Purkinje cells to prevent arrhythmias |
| Moore et al 46 | Mouse | RyR2 | R176Q | Adeno‐associated virus type 9–mediated CRISPR/Cas9 genome editing to specifically disrupt the mutant RYR2 allele, preventing arrhythmias while preserving normal cardiac function |
| Denegri et al 47 | Mouse | CASQ2 | p.Arg33Gln (R33Q) | Adeno‐associated virus type 9–mediated gene transfer of the wild‐type CASQ2 gene, restoring normal calcium handling and interaction with junctin and triadin, effectively preventing and reversing CPVT phenotype |
| Santiago Castillo et al 48 | Mouse | RYR2 | p.Arg4496Cys (R4496C) | Adeno‐associated virus type 9–mediated overexpression of CASQ2, reducing arrhythmic events by promoting RYR2 channel closure |
| Ritschel et al 49 | Mouse | RYR2 | ‐ | Chronic and oral administration of ent‐(+)‐verticilide |
| Reyes Gaido et al 50 , 51 | Mouse | CaMKII | ‐ | Therapeutic strategies targeting calmodulin‐dependent kinase II |
| Hwang et al 52 | Mouse | RYR2 and CASQ2 | ‐ | Flecainide and propafenone shown to prevent CPVT |
| Watanabe et al 53 | Mouse | RYR2 | ‐ | Flecainide demonstrated to inhibit RYR2‐mediated Ca2+ release and prevent CPVT in mouse models |
| Kryshtal et al 54 | Mouse | RYR2 | Flecainide inhibits RYR2‐mediated Ca release, the primary antiarrhythmic mechanism in CPVT | |
| Bueno‐Levy et al 55 | Mouse | CASQ2 | D307H | Ivabradine was ineffective in preventing arrhythmias |
| Blackwell et al 57 | Mouse | RyR2 | ‐ | ent‐verticilide showed dose‐dependent antiarrhythmic efficacy with favorable pharmacokinetics |
| Devalla et al 21 | CPVT‐patient iPSC‐CMs | TECRL |
p. Arg196Gln c.331 + 1G > A |
Flecainide significantly reduced triggered activity in TECRL‐mutant hiPSC‐CMs |
| Jung et al 62 | CPVT‐patient iPSC‐CMs |
RYR2 |
p.(Ser406Leu) p.(Pro2328Ser) |
Dantrolene restored normal Ca2+ handling and prevented arrhythmias |
| Itzhaki et al 64 | CPVT‐patient iPSC‐CMs |
RYR2 |
p.(Met4109Arg) | Adrenergic blockers, flecainide, and thapsigargin reduced afterdepolarizations |
| Preininger et al 65 | CPVT‐patient iPSC‐CMs |
RYR2 |
p. (Leu3741Pro) |
β Blockers (nadolol), flecainide; assessed response to adrenergic stimulation |
| Novak et al 67 | CPVT‐patient iPSC‐CMs |
RYR2 |
p. (Ile4587Val) |
Investigated effects of isoproterenol, caffeine, and ryanodine on calcium handling |
| Novak et al 67 and Nijak et al 66 | CPVT‐patient iPSC‐CMs | CASQ2 | p. (Asp307His) | Explored ultrastructural and functional differences between CPVT1 and CPVT2 mutations |
| Pölönen et al 63 | CPVT‐patient iPSC‐CMs | RYR2 | Exon 3 deletion (E3D), L4115F | Tested carvedilol and flecainide; carvedilol resolved L4115F arrhythmias |
| Maizels et al 68 | CPVT‐patient iPSC‐CMs | CASQ2 | p. (Asp307His) | Antiarrhythmic agents including β blockers, flecainide, riluzole showed efficacy, carvedilol stabilizing sarcoplasmic reticulum function |
| Gao et al 69 | CPVT‐patient iPSC‐CMs | CALM2 | p.E46K | Nadolol and flecainide were effective in suppressing abnormal Ca2+ waves caused by the E46K variant in RyR2‐associated arrhythmogenicity |
| Li et al 61 | CPVT‐patient iPSC‐CMs | RYR2 | p.A2254V | Generated hiPSC lines for disease modeling and studying CPVT mechanisms |
CASQ2 indicates cardiac calsequestrin 2; CPVT, catecholaminergic polymorphic ventricular tachycardia; CRISPR, clustered regularly interspaced short palindromic repeats; hiPSC‐CM, human‐induced pluripotent stem cell–derived cardiomyocyte; iPSC‐CM, induced pluripotent stem cell–derived cardiomyocyte; LTCC, L‐type calcium channel; SAN, sinoatrial node; and TECRL, trans‐2,3‐enoyl‐CoA reductase–like protein.
Progress in Tissue Engineering Using hiPSC‐CMs
The advent of 3‐dimensional engineered heart tissues (EHTs) utilizing hiPSC‐CMs has significantly advanced the research on conditions like CPVT. These developments have effectively tackled the issue of hiPSC‐CMs' immaturity, leading to substantial enhancements in their functionality and structure. Approaches to promote cardiomyocyte maturity have been crucial. These strategies involve extended culture durations, the addition of thyroid hormone, and incorporating fatty acids as energy sources. Additionally, coculture methods, using extracellular matrix, and applying mechanical or electrical stimulation in 3‐dimensional cultures have been instrumental in achieving cardiomyocyte maturation. 70 The heart comprises various cell types, not just cardiomyocytes. Studies show that cardiomyocytes represent only about 25% to 35% of the heart's cells, while endothelial cells account for 60%, and fibroblasts are <20%. 71 In specific heart regions, such as the atria and ventricles, the distribution changes, with cardiomyocytes making up 30% to 50% of cells, and endothelial cells and fibroblasts contributing 10% and 20%, respectively. 72 Incorporating this diversity of cell types enhances the physiological relevance of these models, making them more applicable in disease study, drug testing, and cardiotoxicity assessments. The scaffold‐free hanging droplet technique for 3‐dimensional cell culture involves placing iPSC‐CMs in droplets on ultra‐low attachment plates, sometimes adding cardiac fibroblasts and endothelial cells. 73 This technique produces stable 3‐dimensional iPSC‐CM models responsive to various stimuli. However, challenges like limited Ca2+ dye penetration and retention of immature characteristics, such as shorter sarcomeres, are observed. 73 In addition, the absence of hormonal and nonhormonal factors is a very important limitation of the 3‐dimensional model. Combining iPSC‐CMs with human cardiac fibroblasts and coronary artery endothelial cells results in cardiac spheroids that more accurately resemble the in vivo human heart. 74 Despite these advancements, substantial differences limit the utility of even the best 3‐dimensional models, particularly in replicating the full complexity of native heart tissue. Cardiac microtissues, another type of scaffold‐free product, are created by mixing different cell types, including iPSC‐derived endothelial cells, cardiac fibroblasts, and iPSC‐CMs. These cardiac microtissues show mature structures like elongated tubular myofibrils and T‐tubule–like structures, with electrophysiological maturity indicated by action potential notches, effectively replicating disease phenotypes. 75 In scaffold‐based 3‐dimensional cultures, scaffolds made from decellularized extracellular matrix or natural or synthetic polymers are used. 76 These scaffolds aid in the maturation of cardiomyocytes and using adult heart extracellular matrix has been shown to enhance maturation in both 2D and 3D cultures. 77 EHTs, where iPSC‐CMs are cultured on hydrogel scaffolds, display more mature electrophysiological properties and cardiac ultrastructure, aligning more closely with adult cardiac tissue. 78 Progressive stretching of EHTs has been used to further advance maturation, leading to improved contractility and a more mature excitation/contraction coupling. These EHT models are invaluable in channelopathy research, showing less arrhythmogenic activity compared with 2‐dimensional models and better mimicking clinical scenarios. 79 Specifically, in CPVT research, 3‐dimensional models like EHTs are proving to be essential in understanding the pathophysiological mechanisms of arrhythmias by allowing for more accurate modeling of calcium‐handling abnormalities and the effects of β‐adrenergic stimulation. These models also facilitate the development and testing of potential therapeutic interventions in a more in vivo–like environment compared with traditional 2‐dimensional cell cultures. 80
Limitations of hiPSC‐CMs
While the development of iPSC technology has significantly advanced disease modeling, it still faces notable limitations. A primary issue is the immaturity and variability of hiPSC‐CMs, which manifest in altered gene expression, poor sarcomere organization, abnormal morphology, and insufficient T‐tubule formation. 81 These immature characteristics result in less stability and an increased risk of arrhythmic events in hiPSC‐CMs compared with adult cardiomyocytes, reflecting an inadequate replication of disease‐specific phenotypes found in CPVT. 82 The hiPSC‐CMs often do not account for critical factors such as cellular interactions and hormonal regulation in single‐cell studies. 83 Efforts to address their immature phenotype include extending culture times, using nutrient‐rich media, and using various stimulations such as electrical fields and mechanical forces within extracellular matrices and 3‐dimensional cardiac tissues. 84 Moreover, hiPSC‐CMs lack the complexity of natural cardiac tissues, missing essential ion channels and cytoskeleton proteins. Similarly to animal models, hiPSC‐CMs also face challenges regarding their statistical robustness. The variability in hiPSC‐CMs differentiation processes and the immaturity of these cells may introduce inconsistencies in experimental results. Moreover, small sample sizes in hiPSCs studies can lead to issues with statistical power and impact the ability to draw a final conclusion about the pathophysiology and treatment responses. 85 Advances such as engineered heart tissues and organ‐on‐a‐chip technologies aim to enhance the structural complexity and improve the predictive power of these models. 86 While hiPSC‐CMs have proven valuable for drug development and cardiovascular research, their potential as a full human model is restricted due to their disparities with adult human cardiomyocytes. 83 The complexity of genetic interactions and environmental factors in disease manifestation remains difficult to model. Even with advanced genome editing tools like CRISPR/Cas9, challenges persist. 87 Overall, continued research and improvements are needed to address these limitations, with ongoing developments showing promise in enhancing the capabilities and applications of hiPSC technology.
Unanswered Questions and Future Research
Like the “dark side of the moon,” some areas of CPVT remain challenging to study directly, and clinicians must often make decisions with limited evidence. One major area for further research is understanding the full spectrum, including pathogenicity of genetic mutations beyond the commonly studied RYR2 and CASQ2 variants. These mutations often overlap with other cardiomyopathies and channelopathies, suggesting that CPVT may not be confined to the heart alone but could involve multiorgan systems. 88 Additionally, recent findings emphasize the important role of the autonomic nervous system in cardiac dysregulation, where structures like the stellate ganglion contribute to arrhythmogenic mechanisms via neuroimmune pathways. Studies on stellate ganglion function reveal its significant influence on cardiac sympathetic nerve activity, particularly in arrhythmias involving inflammation. Abnormal stellate ganglion activity may provoke sympathetic overexcitation, initiating a cycle of inflammation and arrhythmias. Exploring interventions targeting stellate ganglion function and inflammatory responses may present new strategies for preventing CPVT‐related arrhythmias and enhancing treatment options for cardiovascular dysautonomia. 89 Many studies have shown that CPVT overlaps with neurodevelopmental disorders, 90 particularly intellectual disabilities, indicating that shared pathophysiological mechanisms may involve intracellular calcium handling in both the heart and the brain. 90 Recently, Tonko et al emphasized that autonomic triggers play a critical role in the proarrhythmogenic mechanisms of cardiac channelopathies, including CPVT. 91 Their findings suggest that autonomic regulation, potentially involving Purkinje fiber activity, could be modulated using neuromodulation approaches. By targeting specific G‐protein–coupled receptors, neuropeptides, and central nervous system centers responsible for autonomic control, these emerging strategies may help reduce Purkinje‐mediated ventricular arrhythmias in CPVT. Future studies should explore the role of Purkinje fibers in human CPVT and assess whether ablation techniques may be effective in certain cases. Additionally, the overlap between CPVT and other cardiomyopathies, such as arrhythmogenic right ventricular cardiomyopathy, is not fully understood and requires further investigation to clarify diagnosis and treatment. 92 The role of the implantable cardioverter‐defibrillator in CPVT remains controversial, as recent evidence suggests it may not provide a mortality benefit in all cases. This raises important questions about the appropriate criteria for implantable cardioverter‐defibrillator implantation, especially in patients who have not experienced life‐threatening arrhythmias. 93 Treatment modalities also need refinement. While nonselective β blockers like nadolol and propranolol remain the cornerstone of therapy, many patients require additional interventions such as flecainide or left cardiac sympathetic denervation. 94 In addition, whether several CPVT types may have a variable response to drug treatment has not been systematically studied yet. Pharmacological strategies have expanded in recent years, but the relative efficacy of different treatments, particularly for asymptomatic carriers identified through genetic screening, remains underexplored. Exploring new therapeutic options, including advanced gene‐editing approaches, will be crucial in the coming years, particularly for patients with complex CPVT phenotypes. Given the increasing evidence linking certain RYR2 to seizures, 95 it will also be important to consider a multidisciplinary approach to treatment, integrating insights from neurology. Unanswered questions in CPVT research also include the role of common and rare variants both in disease genes and other genes, epigenetic variation, and other changes that influence the pathogenicity of presumed disease‐causing mutations. Ultimately, collaborative efforts between geneticists, clinicians, and bioengineers will be crucial for addressing these unanswered questions, refining our understanding of CPVT, and developing personalized treatment approaches.
Conclusions
The exploration of CPVT through diverse experimental models has significantly enriched our understanding of its pathophysiology and potential treatment strategies. Animal models have provided essential insights into the systemic physiological and molecular dynamics of CPVT, while hiPSC‐CMs have facilitated detailed genotype–phenotype analyses and the evaluation of personalized therapeutic interventions. These models, especially when integrated with advanced technologies such as CRISPR/Cas9 and 3‐dimensional cardiac tissues, have substantially advanced our capability to replicate human cardiac pathology and assess pharmacological responses effectively. Despite their transformative impacts, each model carries inherent limitations that highlight the need for continuous refinement. The collective insights from these models drive the development of targeted therapies, aiming to reduce the clinical burden of this potentially fatal condition.
Sources of Funding
This research was funded by the European Union's Horizon 2020 research and innovation program under grant agreement number 739593 to Dr Hamdani; DFG (Deutsche Forschungsgemeinschaft) HA 7512/2–4 and HA 7512/2–1 to Dr Hamdani; Heinrich und Alma Vogelsang Stiftung to L. Schneider; a grant from the Innovations Forum program of the Medical Faculty, RUB to Dr El‐Battrawy and Dr Hamdani number IF‐023‐22 and No. IF‐034‐22; and the Hector‐Stiftung (No. MED1814, M2401) to Dr Hamdani, I. Dr El‐Battrawy, and Dr Akin and the German Heart Foundation (F/17/23) to Dr El‐Battrawy. Dr. El‐Battrawy received funding from the Else‐Kröner‐Fresenius foundation.
Disclosures
None.
For Sources of Funding and Disclosures, see page 11.
This manuscript was sent to Kevin F. Kwaku, MD, PhD, Associate Editor, for review by expert referees, editorial decision, and final disposition.
Contributor Information
Ibrahim Akin, Email: ibrahim.el-battrawy@ruhr-uni-bochum.de.
Ibrahim El‐Battrawy, Email: ibrahim.el-battrawy@ruhr-uni-bochum.de.
References
- 1. Marx A, Lange B, Nalenz C, Hoffmann B, Rostock T, Konrad T. A 35‐year effective treatment of catecholaminergic polymorphic ventricular tachycardia with propafenone. HeartRhythm Case Rep. 2019;5:74–77. doi: 10.1016/j.hrcr.2018.04.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Kallas D, Lamba A, Roston TM, Arslanova A, Franciosi S, Tibbits GF, Sanatani S. Pediatric catecholaminergic polymorphic ventricular tachycardia: a translational perspective for the clinician‐scientist. Int J Mol Sci. 2021;22:9293. doi: 10.3390/ijms22179293 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Olubando D, Hopton C, Eden J, Caswell R, Lowri Thomas N, Roberts SA, Morris‐Rosendahl D, Venetucci L, Newman WG. Classification and correlation of RYR2 missense variants in individuals with catecholaminergic polymorphic ventricular tachycardia reveals phenotypic relationships. J Hum Genet. 2020;65:531–539. doi: 10.1038/s10038-020-0738-6 [DOI] [PubMed] [Google Scholar]
- 4. Postma AV. Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. J Med Genet. 2005;42:863–870. doi: 10.1136/jmg.2004.028993 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Abbas M, Miles C, Behr E. Catecholaminergic polymorphic ventricular tachycardia. Arrhythmia Electrophysiol Rev. 2022;11:78–80. doi: 10.15420/aer.2022.09 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Singh M, Morin DP, Link MS. Sudden cardiac death in long QT syndrome (LQTS), Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia (CPVT). Prog Cardiovasc Dis. 2019;62:227–234. doi: 10.1016/j.pcad.2019.05.006 [DOI] [PubMed] [Google Scholar]
- 7. El‐Battrawy I, Mügge A, Akin I, Nguyen HP, Milting H, Aweimer A. Ion channel diseases as a cause of sudden cardiac death in young people: aspects of their diagnosis, treatment, and pathogenesis. Dtsch Arztebl Int. 2024;20:665–672. doi: 10.3238/arztebl.m2024.0130 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Mohamed U, Gollob MH, Gow RM, Krahn AD. Sudden cardiac death despite an implantable cardioverter‐defibrillator in a young female with catecholaminergic ventricular tachycardia. Heart Rhythm. 2006;3:1486–1489. doi: 10.1016/j.hrthm.2006.08.018 [DOI] [PubMed] [Google Scholar]
- 9. Ammirati E, Contri R, Coppini R, Cecchi F, Frigerio M, Olivotto I. Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives. Eur J Heart Fail. 2016;18:1106–1118. doi: 10.1002/ejhf.541 [DOI] [PubMed] [Google Scholar]
- 10. Kannankeril PJ, Moore JP, Cerrone M, Priori SG, Kertesz NJ, Ro PS, Batra AS, Kaufman ES, Fairbrother DL, Saarel EV, et al. Efficacy of flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia. JAMA Cardiol. 2017;2:759–766. doi: 10.1001/jamacardio.2017.1320 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Bergeman AT, Wilde AAM, van der Werf C. Catecholaminergic polymorphic ventricular tachycardia. Card Electrophysiol Clin. 2023;15:293–305. doi: 10.1016/j.ccep.2023.04.002 [DOI] [PubMed] [Google Scholar]
- 12. Aweimer A, Mügge A, Akin I, El‐Battrawy I. Asymptomatische ionenkanalerkrankungen. Herzschrittmacherther Elektrophysiol. 2023;34:101–108. doi: 10.1007/s00399-023-00937-4 [DOI] [PubMed] [Google Scholar]
- 13. Könemann H, Dagres N, Merino JL, Sticherling C, Zeppenfeld K, Tfelt‐Hansen J, Eckardt L. Spotlight on the 2022 ESC guideline management of ventricular arrhythmias and prevention of sudden cardiac death: 10 novel key aspects. Europace. 2023;25:1–12. doi: 10.1093/europace/euad091 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Capes E, Loaiza R, Valdivia HH. Ryanodine Receptors. Skelet Muscle. 2011;1:18. doi: 10.1186/2044-5040-1-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Priori SG, Mazzanti A, Santiago DJ, Kukavica D, Trancuccio A, Kovacic JC. Precision medicine in catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol. 2021;77:2592–2612. doi: 10.1016/j.jacc.2020.12.073 [DOI] [PubMed] [Google Scholar]
- 16. Hou C, Jiang X, Zhang Y, Xu M, Sun X, Jia J, Li Y, Zhao Y, Xie L, Xiao T. A de novo heterozygous cardiac ryanodine receptor gene (RYR2) mutation in a catecholaminergic polymorphic ventricular tachycardia patient. Gene Rep. 2019;16:100439. doi: 10.1016/j.genrep.2019.100439 [DOI] [Google Scholar]
- 17. Terentyev D, Hamilton S. Regulation of sarcoplasmic reticulum Ca2+ release by serine‐threonine phosphatases in the heart. J Mol Cell Cardiol. 2016;101:156–164. doi: 10.1016/j.yjmcc.2016.08.020 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Zhao Y‐T, Valdivia CR, Gurrola GB, Powers PP, Willis BC, Moss RL, Jalife J, Valdivia HH. Arrhythmogenesis in a catecholaminergic polymorphic ventricular tachycardia mutation that depresses ryanodine receptor function. Proc Natl Acad Sci. 2015;11:1669–1677. doi: 10.1073/pnas.1419795112 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Ylänen K, Poutanen T, Hiippala A, Swan H, Korppi M. Catecholaminergic polymorphic ventricular tachycardia. Eur J Pediatr. 2010;169:535–542. doi: 10.1007/s00431-010-1154-2 [DOI] [PubMed] [Google Scholar]
- 20. Walsh R, Adler A, Amin AS, Abiusi E, Care M, Bikker H, Amenta S, Feilotter H, Nannenberg EA, Mazzarotto F, et al. Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death. Eur Heart J. 2022;43:1500–1510. doi: 10.1093/eurheartj/ehab687 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Devalla HD, Gélinas R, Aburawi EH, Beqqali A, Goyette P, Freund C, Chaix M‐A, Tadros R, Jiang H, Le Béchec A, et al. TECRL, a new life‐threatening inherited arrhythmia gene associated with overlapping clinical features of both LQTS and CPVT. EMBO Mol Med. 2016;8:1390–1408. doi: 10.15252/emmm.201505719 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Deb A, Tow BD, Qing Y, Walker M, Hodges ER, Stewart JA, Knollmann BC, Zheng Y, Wang Y, Liu B. Genetic inhibition of mitochondrial permeability transition pore exacerbates ryanodine receptor 2 dysfunction in arrhythmic disease. Cells. 2023;12:204. doi: 10.3390/cells12020204 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Gonano LA, Jones PP. FK506‐binding proteins 12 and 12.6 (FKBPs) as regulators of cardiac ryanodine receptors: insights from new functional and structural knowledge. Channels. 2017;11:415–425. doi: 10.1080/19336950.2017.1344799 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Jiang D, Xiao B, Yang D, Wang R, Choi P, Zhang L, Cheng H, Chen SRW. RyR2 mutations linked to ventricular tachycardia and sudden death reduce the threshold for store‐overload‐induced Ca2+ release (SOICR). Proc Natl Acad Sci. 2004;101:13062–13067. doi: 10.1073/pnas.0402388101 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Sumitomo N. Current topics in catecholaminergic polymorphic ventricular tachycardia. J Arrhythm. 2016;32:344–351. doi: 10.1016/j.joa.2015.09.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Pappone C, Negro G, Ciconte G. Ventricular fibrillation ablation in cardiomyopathies and arrhythmic storm. Europ Heart J Suppl. 2021;23:E112–E117. doi: 10.1093/eurheartj/suab104 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Manolis AA, Manolis TA, Apostolopoulos EJ, Apostolaki NE, Melita H, Manolis AS. The role of the autonomic nervous system in cardiac arrhythmias: the neuro‐cardiac Axis, more foe than friend? Trends Cardiovasc Med. 2021;31:290–302. doi: 10.1016/j.tcm.2020.04.011 [DOI] [PubMed] [Google Scholar]
- 28. Swaminathan PD, Purohit A, Hund TJ, Anderson ME. Calmodulin‐dependent protein kinase II: linking heart failure and arrhythmias. Circ Res. 2012;110:1661–1677. doi: 10.1161/CIRCRESAHA.111.243956 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Dobrev D, Wehrens XHT. Mouse models of cardiac arrhythmias. Circ Res. 2018;123:332–334. doi: 10.1161/CIRCRESAHA.118.313406 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Liu B, Walton SD, Ho H, Belevych AE, Tikunova SB, Bonilla I, Shettigar V, Knollmann BC, Priori SG, Volpe P, et al. Gene transfer of engineered calmodulin alleviates ventricular arrhythmias in a Calsequestrin‐associated mouse model of catecholaminergic polymorphic ventricular tachycardia. J Am Heart Assoc. 2018;7:e008155. doi: 10.1161/JAHA.117.008155 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Veress R, Martin BY, Hamilton S, Bogdanov V, Terentyeva R, Perger F, Soltisz AM, Tikunova S, Veeraraghavan R, Gyorke S, et al. Reduction of SK current in rat CPVT model with heterozygous calmodulin 3 mutation D132E is caused by impaired intracellular Ca2+ homeostasis. Biophys J. 2023;122:521a. doi: 10.1016/j.bpj.2022.11.2769 [DOI] [Google Scholar]
- 32. Horváth A, Giammarino LOC, Alerni N, Barbieri M, Louradour J, Nimani S, Matas L, Odening KE. Sex differences in cellular Na+‐Ca2+‐handling properties in rabbit atrial cardiomyocytes. Biophys J. 2024;123:457a–458a. doi: 10.1016/j.bpj.2023.11.2781 [DOI] [Google Scholar]
- 33. Sieliwonczyk E, Vandendriessche B, Claes C, Mayeur E, Alaerts M, Holmgren P, Canter Cremers T, Snyders D, Loeys B, Schepers D. Improved selection of zebrafish CRISPR editing by early next‐generation sequencing based genotyping. Sci Rep. 2023;13:1491. doi: 10.1038/s41598-023-27503-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Di Baldassarre A, Cimetta E, Bollini S, Gaggi G, Ghinassi B. Human‐induced pluripotent stem cell technology and cardiomyocyte generation: Progress and clinical applications. Cells. 2018;7:48. doi: 10.3390/cells7060048 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Park S‐J, Zhang D, Qi Y, Li Y, Lee KY, Bezzerides VJ, Yang P, Xia S, Kim SL, Liu X, et al. Insights into the pathogenesis of catecholaminergic polymorphic ventricular tachycardia from engineered human heart tissue. Circulation. 2019;140:390–404. doi: 10.1161/CIRCULATIONAHA.119.039711 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Arbel‐Ganon L, Behar JA, Gómez AM, Yaniv Y. Distinct mechanisms mediate pacemaker dysfunction associated with catecholaminergic polymorphic ventricular tachycardia mutations: insights from computational modeling. J Mol Cell Cardiol. 2020;143:85–95. doi: 10.1016/j.yjmcc.2020.04.017 [DOI] [PubMed] [Google Scholar]
- 37. Mohamed U, Napolitano C, Priori SG. Molecular and electrophysiological bases of catecholaminergic polymorphic ventricular tachycardia. J Cardiovasc Electrophysiol. 2007;18:791–797. doi: 10.1111/j.1540-8167.2007.00766.x [DOI] [PubMed] [Google Scholar]
- 38. Veress R, Belevych AE, Terentyeva R, Perger F, Gorr M, Bogdanov V, Pokrass A, Walton SD, Charif A, Davis JP, et al. Calmodulin mutation D132E in different genes causes different arrhythmia phenotypes. Biophys J. 2024;123:458a. doi: 10.1016/j.bpj.2023.11.2782 [DOI] [Google Scholar]
- 39. Deb A, Knollmann BC, Liu B. Modulating mitochondrial phosphate transport shapes intracellular Ca signaling to impact arrhythmogenesis. Biophys J. 2024;123:456a. doi: 10.1016/j.bpj.2023.11.2776 [DOI] [Google Scholar]
- 40. Lin S, Chen S, Lin Q, Xiao T, Hou C, Xie L. Transcriptome analysis of effects of Tecrl deficiency on cardiometabolic and calcium regulation in cardiac tissue. Open Med. 2024;19:20230880. doi: 10.1515/med-2023-0880 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Pavlaki N, de la Serna Buzon S, Sweat M, Pu WT, Marx S, Bezzerides VJ. Abstract P3135: in vivo dissection of CaMKII‐mediated arrhythmias in CPVT. Circ Res. 2023;133(Suppl_1):2817–2834. doi: 10.1161/res.133.suppl_1.P3135 [DOI] [Google Scholar]
- 42. Neco P, Torrente AG, Mesirca P, Zorio E, Liu N, Priori SG, Napolitano C, Richard S, Benitah J‐P, Mangoni ME, et al. Paradoxical effect of increased diastolic Ca2+ release and decreased sinoatrial node activity in a mouse model of catecholaminergic polymorphic ventricular tachycardia. Circulation. 2012;126:392–401. doi: 10.1161/CIRCULATIONAHA.111.075382 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43. Veith M, El‐Battrawy I, Roterberg G, Raschwitz L, Lang S, Wolpert C, Schimpf R, Zhou X, Akin I, Borggrefe M. Long‐term follow‐up of patients with catecholaminergic polymorphic ventricular arrhythmia. J Clin Med. 2020;9:903. doi: 10.3390/jcm9040903 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44. Yin L, Zahradnikova A, Rizzetto R, Boncompagni S, Rabesahala de Meritens C, Zhang Y, Joanne P, Marqués‐Sulé E, Aguilar‐Sánchez Y, Fernández‐Tenorio M, et al. Impaired binding to Junctophilin‐2 and Nanostructural alteration in CPVT mutation. Circ Res. 2021;129:35–52. doi: 10.1161/CIRCRESAHA.121.319094 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Blackwell DJ, Faggioni M, Wleklinski MJ, Gomez‐Hurtado N, Venkataraman R, Gibbs CE, Baudenbacher FJ, Gong S, Fishman GI, Boyle PM, et al. The Purkinje–myocardial junction is the anatomic origin of ventricular arrhythmia in CPVT. JCI Insight. 2022;7:e151893. doi: 10.1172/jci.insight.151893 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Moore OM, Aguilar‐Sanchez Y, Lahiri SK, Hulsurkar MM, Navarro‐Garcia JA, Word TA, Keefe JA, Barazi D, Munivez EM, et al. Long‐term efficacy and safety of cardiac genome editing for catecholaminergic polymorphic ventricular tachycardia. J Cardiovasc Aging. 2024;4:44–52. doi: 10.20517/jca.2023.42 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47. Denegri M, Bongianino R, Lodola F, Boncompagni S, De Giusti VC, Avelino‐Cruz JE, Liu N, Persampieri S, Curcio A, Esposito F, et al. Single delivery of an adeno‐associated viral construct to transfer the CASQ2 gene to Knock‐in mice affected by catecholaminergic polymorphic ventricular tachycardia is able to cure the disease from birth to advanced age. Circulation. 2014;129:2673–2681. doi: 10.1161/CIRCULATIONAHA.113.006901 [DOI] [PubMed] [Google Scholar]
- 48. Santiago Castillo D, Bongianino R, Trancuccio A, Kukavica D, Tarifa C, Denegri M, Mazzanti A, Priori SG. Overexpression of cardiac Calsequestrin as a novel gene‐therapy approach to treat CPVT1: in silico and in vivo proves of principle. Eur Heart J. 2023;44:ehad655.3135. doi: 10.1093/eurheartj/ehad655.3135 [DOI] [Google Scholar]
- 49. Ritschel P, Blackwell DJ, Thorpe MP, Johnston JN, Akers SW, Knollmann BC. The RyR2‐selective inhibitor Ent‐verticilide prevents ventricular arrhythmia with chronic and Oral dosing. Biophys J. 2024;123:535a,j.bpj.2023.11.3228. doi: 10.1016/j.bpj.2023.11.3228 [DOI] [Google Scholar]
- 50. Reyes Gaido OE, Nkashama LJ, Schole KL, Wang Q, Umapathi P, Mesubi OO, Konstantinidis K, Luczak ED, Anderson ME. CaMKII as a therapeutic target in cardiovascular disease. Annu Rev Pharmacol Toxicol. 2023;63:249–272. doi: 10.1146/annurev-pharmtox-051421-111814 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51. Reyes Gaido OE, Pavlaki N, Granger JM, Mesubi OO, Liu B, Lin BL, Long A, Walker D, Mayourian J, et al. An improved reporter identifies ruxolitinib as a potent and cardioprotective CaMKII inhibitor. Sci Transl Med. 2023;15:eabq7839. doi: 10.1126/scitranslmed.abq7839 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52. Hwang HS, Hasdemir C, Laver D, Mehra D, Turhan K, Faggioni M, Yin H, Knollmann BC. Inhibition of cardiac Ca 2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol. 2011;4:128–135. doi: 10.1161/CIRCEP.110.959916 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, Duff HJ, Roden DM, Wilde AAM, Knollmann BC. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009;15:380–383. doi: 10.1038/nm.1942 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54. Kryshtal DO, Blackwell DJ, Egly CL, Smith AN, Batiste SM, Johnston JN, Laver DR, Knollmann BC. RYR2 channel inhibition is the principal mechanism of flecainide action in CPVT. Circ Res. 2021;128:321–331. doi: 10.1161/CIRCRESAHA.120.316819 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55. Bueno‐Levy H, Weisbrod D, Yadin D, Haron‐Khun S, Peretz A, Hochhauser E, Arad M, Attali B. The hyperpolarization‐activated cyclic‐nucleotide‐gated channel blocker ivabradine does not prevent arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Front Pharmacol. 2020;10:1566. doi: 10.3389/fphar.2019.01566 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56. Di Pasquale E, Lodola F, Miragoli M, Denegri M, Avelino‐Cruz JE, Buonocore M, Nakahama H, Portararo P, Bloise R, Napolitano C, et al. CaMKII inhibition rectifies arrhythmic phenotype in a patient‐specific model of catecholaminergic polymorphic ventricular tachycardia. Cell Death Dis. 2013;4:e843. doi: 10.1038/cddis.2013.369 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57. Blackwell DJ, Smith AN, Do T, Gochman A, Schmeckpeper J, Hopkins CR, Akers WS, Johnston JN, Knollmann BC. In vivo pharmacokinetic and pharmacodynamic properties of the antiarrhythmic molecule Ent ‐Verticilide. JPharmacol Exp Therap. 2023;385:205–213. doi: 10.1124/jpet.122.001455 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58. Keeley TP, Mann GE. Defining physiological Normoxia for improved translation of cell physiology to animal models and humans. Physiol Rev. 2019;99:161–234. doi: 10.1152/physrev.00041.2017 [DOI] [PubMed] [Google Scholar]
- 59. Bate ST, Clark RA. The design and statistical analysis of animal experiments. Cambridge University Press; 2014. doi: 10.1017/CBO9781139344319 [DOI] [Google Scholar]
- 60. Varzideh F, Mone P, Santulli G. Bioengineering strategies to create 3D cardiac constructs from human induced pluripotent stem cells. Bioengineering. 2022;9:168. doi: 10.3390/bioengineering9040168 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61. Li W, Henze S, Luo X, Ulbricht Y, Richter A, Di Donato N, Wilde AAM, Guan K. Generation of IPSC lines from CPVT patient carrying heterozygous mutation p.A2254V in the ryanodine receptor 2 gene. Stem Cell Res. 2021;53:102259. doi: 10.1016/j.scr.2021.102259 [DOI] [PubMed] [Google Scholar]
- 62. Jung CB, Moretti A, Mederos y Schnitzler M, Iop L, Storch U, Bellin M, Dorn T, Ruppenthal S, Pfeiffer S, Goedel A, et al. Dantrolene rescues arrhythmogenic RYR2 defect in a patient‐specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO Mol Med. 2012;4:180–191. doi: 10.1002/emmm.201100194 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63. Pölönen RP, Swan H, Aalto‐Setälä K. Mutation‐specific differences in arrhythmias and drug responses in CPVT patients: simultaneous patch clamp and video imaging of IPSC derived cardiomyocytes. Mol Biol Rep. 2020;47:1067–1077. doi: 10.1007/s11033-019-05201-y [DOI] [PubMed] [Google Scholar]
- 64. Itzhaki I, Maizels L, Huber I, Gepstein A, Arbel G, Caspi O, Miller L, Belhassen B, Nof E, Glikson M, et al. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient‐specific human‐induced pluripotent stem cells. J Am Coll Cardiol. 2012;60:990–1000. doi: 10.1016/j.jacc.2012.02.066 [DOI] [PubMed] [Google Scholar]
- 65. Preininger MK, Jha R, Maxwell JT, Wu Q, Singh M, Wang B, Dalal A, Mceachin ZT, Rossoll W, Hales CM, et al. Human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient‐specific drug responses. Dis Model Mech. 2016;9(9):927–939. doi: 10.1242/dmm.026823 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66. Nijak A, Saenen J, Labro AJ, Schepers D, Loeys BL, Alaerts M. IPSC‐cardiomyocyte models of brugada syndrome—achievements, challenges and future perspectives. Int J Mol Sci. 2021;22:2825. doi: 10.3390/ijms22062825 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67. Novak A, Barad L, Lorber A, Gherghiceanu M, Reiter I, Eisen B, Eldor L, Itskovitz‐Eldor J, Eldar M, Arad M, et al. Functional abnormalities in IPSC‐derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or Calsequestrin mutations. J Cell Mol Med. 2015;19:2006–2018. doi: 10.1111/jcmm.12581 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68. Maizels L, Huber I, Arbel G, Tijsen AJ, Gepstein A, Khoury A, Gepstein L. Patient‐specific drug screening using a human induced pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia type 2. Circ Arrhythm Electrophysiol. 2017;10:e004725. doi: 10.1161/CIRCEP.116.004725 [DOI] [PubMed] [Google Scholar]
- 69. Gao J, Makiyama T, Yamamoto Y, Kobayashi T, Aoki H, Maurissen TL, Wuriyanghai Y, Kashiwa A, Imamura T, Aizawa T, et al. Novel calmodulin variant p.E46K associated with severe catecholaminergic polymorphic ventricular tachycardia produces robust arrhythmogenicity in human induced pluripotent stem cell–derived cardiomyocytes. Circ Arrhythm Electrophysiol. 2023;16:e011387. doi: 10.1161/CIRCEP.122.011387 [DOI] [PubMed] [Google Scholar]
- 70. Ahmed RE, Anzai T, Chanthra N, Uosaki H. A brief review of current maturation methods for human induced pluripotent stem cells‐derived cardiomyocytes. Front Cell Dev Biol. 2020;8:178. doi: 10.3389/fcell.2020.00178 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71. Litviňuková M, Talavera‐López C, Maatz H, Reichart D, Worth CL, Lindberg EL, Kanda M, Polanski K, Heinig M, Lee M, et al. Cells of the adult human heart. Nature. 2020;588:466–472. doi: 10.1038/s41586-020-2797-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72. Pinto AR, Ilinykh A, Ivey MJ, Kuwabara JT, D'Antoni ML, Debuque R, Chandran A, Wang L, Arora K, Rosenthal NA, et al. Revisiting cardiac cellular composition. Circ Res. 2016;118:400–409. doi: 10.1161/CIRCRESAHA.115.307778 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73. Ergir E, Oliver‐De La Cruz J, Fernandes S, Cassani M, Niro F, Pereira‐Sousa D, Vrbský J, Vinarský V; Perestrelo , et al. Generation and maturation of human IPSC‐derived 3D organotypic cardiac microtissues in Long‐term culture. Sci Rep. 2022;12:17409. doi: 10.1038/s41598-022-22225-w [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74. Sharma P, Gentile C. Cardiac spheroids as in vitro bioengineered heart tissues to study human heart pathophysiology. J Vis Exp. 2021:e61962. doi: 10.3791/61962 [DOI] [PubMed] [Google Scholar]
- 75. Giacomelli E, Meraviglia V, Campostrini G, Cochrane A, Cao X, van Helden RWJ, Krotenberg Garcia A, Mircea M, Kostidis S, Davis RP, et al. Human‐IPSC‐derived cardiac stromal cells enhance maturation in 3D cardiac microtissues and reveal non‐cardiomyocyte contributions to heart disease. Cell Stem Cell. 2020;26:862–879.e11. doi: 10.1016/j.stem.2020.05.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76. Chen Y, Chan JPY, Wu J, Li R, Santerre JP. Compatibility and function of human induced pluripotent stem cell derived cardiomyocytes on an electrospun nanofibrous scaffold, generated from an ionomeric polyurethane composite. J Biomed Mater Res A. 2022;110:1932–1943. doi: 10.1002/jbm.a.37428 [DOI] [PubMed] [Google Scholar]
- 77. Fong AH, Romero‐López M, Heylman CM, Keating M, Tran D, Sobrino A, Tran AQ, Pham HH, Fimbres C, Gershon PD, et al. Three‐dimensional adult cardiac extracellular matrix promotes maturation of human induced pluripotent stem cell‐derived cardiomyocytes. Tissue Eng Part A. 2016;22:1016–1025. doi: 10.1089/ten.tea.2016.0027 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78. Qin J, van Mil A, Sluijter JPG. Biophysical stretch induced differentiation and maturation of induced pluripotent stem cell‐derived cardiomyocytes. 2023;141–179. doi: 10.1007/978-3-031-23965-6_7 [DOI]
- 79. Hong Y, Zhao Y, Li H, Yang Y, Chen M, Wang X, Luo M, Wang K. Engineering the maturation of stem cell‐derived cardiomyocytes. Front Bioeng Biotechnol. 2023;11:1155052. doi: 10.3389/fbioe.2023.1155052 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80. Criscione J, Rezaei Z, Hernandez Cantu CM, Murphy S, Shin SR, Kim D‐H. Heart‐on‐a‐Chip platforms and biosensor integration for disease modeling and phenotypic drug screening. Biosens Bioelectron. 2023;220:114840. doi: 10.1016/j.bios.2022.114840 [DOI] [PubMed] [Google Scholar]
- 81. Hamledari H, Asghari P, Jayousi F, Aguirre A, Maaref Y, Barszczewski T, Ser T, Moore E, Wasserman W, Klein Geltink R, et al. Using human induced pluripotent stem cell‐derived cardiomyocytes to understand the mechanisms driving cardiomyocyte maturation. Fron Cardiovasc Med. 2022;9:481–491. doi: 10.3389/fcvm.2022.967659 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82. Paci M, Penttinen K, Pekkanen‐Mattila M, Koivumäki JT. Arrhythmia mechanisms in human induced pluripotent stem cell–derived cardiomyocytes. J Cardiovasc Pharmacol. 2021;77:300–316. doi: 10.1097/FJC.0000000000000972 [DOI] [PubMed] [Google Scholar]
- 83. Gharanei M, Shafaattalab S, Sangha S, Gunawan M, Laksman Z, Hove‐Madsen L, Tibbits GF. Atrial‐specific HiPSC‐derived cardiomyocytes in drug discovery and disease modeling. Methods. 2022;203:364–377. doi: 10.1016/j.ymeth.2021.06.009 [DOI] [PubMed] [Google Scholar]
- 84. Salem T, Frankman Z, Churko JM. Tissue engineering techniques for induced pluripotent stem cell derived three‐dimensional cardiac constructs. Tissue Eng Part B Rev. 2022;28:891–911. doi: 10.1089/ten.teb.2021.0088 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85. Bernstein D. Induced pluripotent stem cell‐derived cardiomyocytes: a platform for testing for drug cardiotoxicity. Prog Pediatr Cardiol. 2017;46:2–6. doi: 10.1016/j.ppedcard.2017.07.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86. Lippi M, Stadiotti I, Pompilio G, Sommariva E. Human cell modeling for cardiovascular diseases. Int J Mol Sci. 2020;21(17):6388. doi: 10.3390/ijms21176388 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87. Parrotta EI, Lucchino V, Scaramuzzino L, Scalise S, Cuda G. Modeling cardiac disease mechanisms using induced pluripotent stem cell‐derived cardiomyocytes: Progress, promises and challenges. Int J Mol Sci. 2020;21:4354. doi: 10.3390/ijms21124354 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88. Pflaumer A, Wilde AAM, Charafeddine F, Davis AM. 50 years of catecholaminergic polymorphic ventricular tachycardia (CPVT)—time to explore the dark side of the moon. Heart Lung Circ. 2020;29:520–528. doi: 10.1016/j.hlc.2019.10.013 [DOI] [PubMed] [Google Scholar]
- 89. Habecker BA, Bers DM, Birren SJ, Chang R, Herring N, Kay MW, Li D, Mendelowitz D, Mongillo M, Montgomery JM, et al. Molecular and cellular Neurocardiology in heart disease. J Physiol. 2024:1–40. doi: 10.1113/JP284739 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 90. Lieve KVV, Verhagen JMA, Wei J, Bos JM, van der Werf C, Rosés i Noguer F, Mancini GMS, et al. Linking the heart and the brain: neurodevelopmental disorders in patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2019;16:220–228. doi: 10.1016/j.hrthm.2018.08.025 [DOI] [PubMed] [Google Scholar]
- 91. Tonko JB, Lambiase PD. The proarrhythmogenic role of autonomics and emerging neuromodulation approaches to prevent sudden death in cardiac ion channelopathies. Cardiovasc Res. 2024;120:114–131. doi: 10.1093/cvr/cvae009 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 92. Siu A, Tandanu E, Ma B, Osas EE, Liu H, Liu T, Chou OHI, Huang H, Tse G. Precision medicine in catecholaminergic polymorphic ventricular tachycardia: recent advances toward personalized Care. Ann Pediatr Cardiol. 2023;16:431–446. doi: 10.4103/apc.apc_96_23 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 93. Eckert H, El‐Battrawy I, Veith M, Roterberg G, Kowitz J, Lang S, Zhou X, Akin I, Mügge A, Aweimer A. Pooled analysis of complications with transvenous ICD compared to subcutaneous ICD in patients with catecholaminergic polymorphic ventricular arrhythmia. J Person Med. 2022;12:536. doi: 10.3390/jpm12040536 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 94. Aggarwal A, Stolear A, Alam MM, Vardhan S, Dulgher M, Jang S‐J, Zarich SW. Catecholaminergic polymorphic ventricular tachycardia: clinical characteristics, diagnostic evaluation and therapeutic strategies. J Clin Med. 2024;13:1781. doi: 10.3390/jcm13061781 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 95. Xing Y, Cui T, Sun F. A novel RyR2 mutation associated with Co‐morbid catecholaminergic polymorphic ventricular tachycardia (CPVT) and benign epilepsy with centrotemporal spikes (BECTS). J Electrocardiol. 2024;84:75–80. doi: 10.1016/j.jelectrocard.2024.03.013 [DOI] [PubMed] [Google Scholar]
